Plasma cell myeloma
Not recruitingComparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant
Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant
- Disease:Plasma cell myeloma
- Substances:BortezomibIsatuximab+2
Germany- Participants:18–64 years · 65+ years
- Substances:Bortezomib
- Sponsor:Universitaetsklinikum Heidelberg AöR









